Physician profile
Adam Powers
NPI 1679231625
$1,696.45
in general payments reported to CMS, 2019-2025
25 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $421 · 2023: $314 · 2024: $530 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $349.92 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Collegium Pharmaceutical, INC. | $253.04 | 2023-2025 | Belbuca, Xtampza |
| Foundation Fusion Solutions, LLC | $144.64 | 2025 | |
| Abbvie INC. | $110.28 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.85 | 2022 | |
| Glaxosmithkline, LLC. | $60.56 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Valinor Pharma, LLC | $59.21 | 2024 | Movantik |
| Averitas Pharma INC. | $59.20 | 2023-2025 | Qutenza |
| Lilly USA, LLC | $59.15 | 2023-2024 | Mounjaro, Trulicity, Jardiance |
| Virtus Pharmaceuticals LLC | $58.93 | 2024-2025 | Levorphanol Tartrate |
| Lundbeck LLC | $58.61 | 2023-2024 | Vyepti, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.72 | 2022-2025 | Relistor |
| Novo Nordisk INC | $48.51 | 2023-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $44.63 | 2023-2024 | |
| Si-Bone, INC. | $40.08 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $35.84 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $32.89 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.19 | 2023-2024 | Jardiance |
| Kyowa Kirin, INC. | $23.57 | 2023 | Crysvita |
| Spr Therapeutics, INC | $22.35 | 2025 | Sprint Pns System |
| Nevro Corp. | $18.39 | 2022 | |
| Amgen INC. | $16.86 | 2023 | Otezla, Repatha |
| Sanofi Pasteur INC. | $16.22 | 2023 | |
| Curonix LLC | $15.32 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ferring Pharmaceuticals INC. | $13.49 | 2025 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.